Mesenchymal stromal cell therapy for liver diseases

Mohammed Alfaifi; Young Woo Eom; Philip N. Newsome; Soon Koo Baik

doi:10.1016/j.jhep.2018.01.030

Mesenchymal stromal cell therapy for liver diseases

Mohammed Alfaifi, Young Woo Eom, Philip N. Newsome, Soon Koo Baik

Internal Medicine

Research output: Contribution to journal › Review article › peer-review

107 Citations (Scopus)

Abstract

The therapeutic potential of mesenchymal stromal cells (MSCs) in the treatment of liver fibrosis is predominantly based on their immunosuppressive properties, and their ability to secrete various trophic factors. This potential has been investigated in clinical and preclinical studies. Although the therapeutic mechanisms of MSC transplantation are still not fully characterised, accumulating evidence has revealed that various trophic factors secreted by MSCs play key therapeutic roles in regeneration by alleviating inflammation, apoptosis, and fibrosis as well as stimulating angiogenesis and tissue regeneration in damaged liver. In this review, we summarise the safety, efficacy, potential transplantation routes and therapeutic effects of MSCs in patients with liver fibrosis. We also discuss some of the key strategies to enhance the functionality of MSCs, which include sorting and/or priming with factors such as cytokines, as well as genetic engineering.

Original language	English
Pages (from-to)	1272-1285
Number of pages	14
Journal	Journal of Hepatology
Volume	68
Issue number	6
DOIs	https://doi.org/10.1016/j.jhep.2018.01.030
Publication status	Published - 2018 Jun

Bibliographical note

Funding Information:
MA is supported by a grant from the Saudi Arabian Cultural Bureau. PNN is supported by the National Institute of Health Research (NIHR) Birmingham Liver Biomedical Research Unit (BRU). The views expressed are those of the authors and not necessarily reflect those of the NHS, the NIHR or the Department of Health.

Funding Information:
YWE and SKB were supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI15C2364, HI17C1365), and a Basic Science Research Program and a Medical Research Center Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2017R1D1A1A02019212 and -2017R1A5A2015369, respectively).

Publisher Copyright:
© 2018 European Association for the Study of the Liver

All Science Journal Classification (ASJC) codes

Hepatology

Access to Document

10.1016/j.jhep.2018.01.030

Cite this

@article{b5fbe50879d6410884d315e07db5ccb0,

title = "Mesenchymal stromal cell therapy for liver diseases",

abstract = "The therapeutic potential of mesenchymal stromal cells (MSCs) in the treatment of liver fibrosis is predominantly based on their immunosuppressive properties, and their ability to secrete various trophic factors. This potential has been investigated in clinical and preclinical studies. Although the therapeutic mechanisms of MSC transplantation are still not fully characterised, accumulating evidence has revealed that various trophic factors secreted by MSCs play key therapeutic roles in regeneration by alleviating inflammation, apoptosis, and fibrosis as well as stimulating angiogenesis and tissue regeneration in damaged liver. In this review, we summarise the safety, efficacy, potential transplantation routes and therapeutic effects of MSCs in patients with liver fibrosis. We also discuss some of the key strategies to enhance the functionality of MSCs, which include sorting and/or priming with factors such as cytokines, as well as genetic engineering.",

author = "Mohammed Alfaifi and Eom, {Young Woo} and Newsome, {Philip N.} and Baik, {Soon Koo}",

note = "Funding Information: MA is supported by a grant from the Saudi Arabian Cultural Bureau. PNN is supported by the National Institute of Health Research (NIHR) Birmingham Liver Biomedical Research Unit (BRU). The views expressed are those of the authors and not necessarily reflect those of the NHS, the NIHR or the Department of Health. Funding Information: YWE and SKB were supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI15C2364, HI17C1365), and a Basic Science Research Program and a Medical Research Center Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2017R1D1A1A02019212 and -2017R1A5A2015369, respectively). Publisher Copyright: {\textcopyright} 2018 European Association for the Study of the Liver",

year = "2018",

month = jun,

doi = "10.1016/j.jhep.2018.01.030",

language = "English",

volume = "68",

pages = "1272--1285",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Mesenchymal stromal cell therapy for liver diseases

AU - Alfaifi, Mohammed

AU - Eom, Young Woo

AU - Newsome, Philip N.

AU - Baik, Soon Koo

N1 - Funding Information: MA is supported by a grant from the Saudi Arabian Cultural Bureau. PNN is supported by the National Institute of Health Research (NIHR) Birmingham Liver Biomedical Research Unit (BRU). The views expressed are those of the authors and not necessarily reflect those of the NHS, the NIHR or the Department of Health. Funding Information: YWE and SKB were supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI15C2364, HI17C1365), and a Basic Science Research Program and a Medical Research Center Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2017R1D1A1A02019212 and -2017R1A5A2015369, respectively). Publisher Copyright: © 2018 European Association for the Study of the Liver

PY - 2018/6

Y1 - 2018/6

N2 - The therapeutic potential of mesenchymal stromal cells (MSCs) in the treatment of liver fibrosis is predominantly based on their immunosuppressive properties, and their ability to secrete various trophic factors. This potential has been investigated in clinical and preclinical studies. Although the therapeutic mechanisms of MSC transplantation are still not fully characterised, accumulating evidence has revealed that various trophic factors secreted by MSCs play key therapeutic roles in regeneration by alleviating inflammation, apoptosis, and fibrosis as well as stimulating angiogenesis and tissue regeneration in damaged liver. In this review, we summarise the safety, efficacy, potential transplantation routes and therapeutic effects of MSCs in patients with liver fibrosis. We also discuss some of the key strategies to enhance the functionality of MSCs, which include sorting and/or priming with factors such as cytokines, as well as genetic engineering.

AB - The therapeutic potential of mesenchymal stromal cells (MSCs) in the treatment of liver fibrosis is predominantly based on their immunosuppressive properties, and their ability to secrete various trophic factors. This potential has been investigated in clinical and preclinical studies. Although the therapeutic mechanisms of MSC transplantation are still not fully characterised, accumulating evidence has revealed that various trophic factors secreted by MSCs play key therapeutic roles in regeneration by alleviating inflammation, apoptosis, and fibrosis as well as stimulating angiogenesis and tissue regeneration in damaged liver. In this review, we summarise the safety, efficacy, potential transplantation routes and therapeutic effects of MSCs in patients with liver fibrosis. We also discuss some of the key strategies to enhance the functionality of MSCs, which include sorting and/or priming with factors such as cytokines, as well as genetic engineering.

UR - http://www.scopus.com/inward/record.url?scp=85044955340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044955340&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2018.01.030

DO - 10.1016/j.jhep.2018.01.030

M3 - Review article

C2 - 29425678

AN - SCOPUS:85044955340

SN - 0168-8278

VL - 68

SP - 1272

EP - 1285

JO - Journal of Hepatology

JF - Journal of Hepatology

IS - 6

ER -

Mesenchymal stromal cell therapy for liver diseases

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this